Publications in collaboration with researchers from Hospital Vega Baja (14)

2023

  1. Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat

    Patient Preference and Adherence, Vol. 17, pp. 839-849

2022

  1. Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 12

  2. Role of vericiguat in the overall etiopathogenesis of heart failure with reduced ejection fraction. Current position

    Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 8-14

  3. Sex Differences in Low-Density Lipoprotein Cholesterol Reduction with PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry

    Journal of Cardiovascular Pharmacology, Vol. 79, Núm. 4, pp. 523-529

  4. Therapeutic approach to patients with heart failure with reduced ejection fraction. The role of vericiguat

    Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 23-29

  5. Vericiguat in heart failure: from scientific evidence to clinical practice

    Revista Clinica Espanola

2020

  1. Nutritional Risk and Mortality at One Year for Elderly Patients Hospitalized with Nonvalvular Atrial Fibrillation. NONAVASC Registry

    Journal of Nutrition, Health and Aging

2019

  1. Correction to: Influence of frailty on anticoagulant prescription and clinical outcomes after 1-year follow-up in hospitalised older patients with atrial fibrillation (Internal and Emergency Medicine, (2019), 14, 1, (59-69), 10.1007/s11739-018-1938-3)

    Internal and Emergency Medicine

2018

  1. Rivaroxaban: searching the integral vascular protection

    Expert Review of Clinical Pharmacology, Vol. 11, Núm. 7, pp. 719-728

2017

  1. Predicting cardiovascular events in familial hypercholesterolemia: The SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study)

    Circulation, Vol. 135, Núm. 22, pp. 2133-2144

2016

  1. Randomized dose-response study of subcutaneous immunotherapy with a Dermatophagoides pteronyssinus extract in patients with respiratory allergy

    Immunotherapy, Vol. 8, Núm. 3, pp. 265-277

2015

  1. Erratum: Antithrombotic treatment in elderly patients with atrial fibrillation: A practical approach [BMC Cardiovascular Disorders, (2015), 15, 143]

    BMC Cardiovascular Disorders

  2. Tratamiento antitrombótico en el paciente anciano con fibrilación auricular

    Revista Clinica Espanola, Vol. 215, Núm. 3, pp. 171-181

2009

  1. Engineering of major house dust mite allergens der p 1 and der p 2 for allergen-specific immunotherapy

    Clinical and Experimental Allergy, Vol. 39, Núm. 7, pp. 1088-1098